secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-02-24T23:59:59+00:00
Accession:  0001193125-23-047460
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

CytomX restates 2018-2021 annual and 2018-2022 quarterly financials due to revenue recognition error
--------------------------------------------------------------------------------

- Restatement affects timing of revenue from collaborations with Bristol-Myers Squibb, Astellas, AbbVie, and Amgen.
- No impact on total revenue, cash position, or cash flows; only timing of revenue recognition changes.
- Material weakness identified in internal control over financial reporting related to ASC 606 application.
- Company plans to amend 2021 Form 10-K and restate 2021 and 2022 quarters in 2022 Form 10-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523047460/0001193125-23-047460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312523047460/d414055d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-047460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer